Application of marine fungus-derived citrinin derivative cladosporin C in preparation of anti-prostatic cancer drugs

By isolated and prepared from the marine fungus Talaromyces sp.SCSIO 41412, the drug resistance problem in existing prostate cancer treatment was solved, effective inhibition of prostate cancer cells was achieved, and new anti-prostate cancer drug selection was provided.

CN118986966APending Publication Date: 2024-11-22SOUTH CHINA SEA INST OF OCEANOLOGY CHINESE ACAD OF SCI
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411089752.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Among the existing treatment methods for prostate cancer, androgen deprivation therapy is prone to lead to drug resistance, resulting in the lack of effective treatment plans for patients with advanced prostate cancer. There is currently no effective cure for prostate cancer.

Method used

The ceramycin derivative cladosporin C was isolated from the fermented substance of the marine fungus Talaromyces sp.SCSIO 41412, and purified by ethyl acetate extraction, normal phase silica gel column chromatography, reverse phase MPLC and semi-preparation HPLC to obtain anti-prostate glands. A compound that is active in cancer cells.

Benefits of technology

Cladosporin C significantly inhibits the proliferation of PC-3 and 22Rv1 prostate cancer cells, with IC50 values ​​of 6.51 and 9.25 μM, respectively, and has potential role in the treatment of prostate cancer. It is a supplementary choice or combination therapy after resistance to androgen receptor antagonist Use medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986966A_ABST
    Figure CN118986966A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a citrinin derivative cladosporin C derived from marine fungi in preparation of a medicine for resisting prostatic cancer. The structural formula of the compound cladosporin C is as shown in formula (I). The compound cladosporin C is prepared and separated from a fermentation product of a marine fungus Talaromyces sp.SCSIO 41412, and the compound cladosporin C is prepared and separated from the fermentation product of the marine fungus Talaromyces sp.SCSIO 41412. The cladosporin C can inhibit proliferation of PC-3 and 22Rv1 prostate cancer cells, has IC50 values of 6.51 mu M and 9.25 mu M respectively, and can be used for preparing the anti-prostate cancer medicine. Therefore, the cladosporin C disclosed by the invention can be used as a supplementary choice or a drug choice for combined treatment after androgen receptor antagonists such as enzalutamide are resistant to drugs, and has important significance on development of marine drug resources in China. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural product application, and specifically relates to a citrinin derivative cladosporin C derived from marine fungi, a preparation method thereof, and an application thereof in the preparation of an anti-prostate cancer drug. Background Art

[0002] Prostate cancer (PCa) is a malignant lesion originating from prostate epithelial cells and is the second most lethal malignant tumor in men after skin cancer. Prostate cancer usually has no specific symptoms in the early stages, but as the disease progresses, a series of compression symptoms and metastatic symptoms will appear. Tumor compression of the urethra can lead to progressive dysuria; compression of the rectum can cause defecation difficulties or intestinal obstruction; compression of the vas deferens may cause ejaculation disorders; compression of nerves may cause perineal pain and radiate to the sciatic nerve. In addition, prostate cancer may also invade the bone marrow, leading to anemia or a decrease in complete blood count. Currently, androgen deprivation therapy (ADT) is the most commonly used treatment for prostate cancer because this lesion is highly dependent on androgens to promote its development. However, most patients will eventually develop resistance to ADT and develop castration-resistant prostate cancer, which is the main reason for the failure of endocrine therapy. Although significant progress has been made in the treatment of metastatic prostate cancer in the past few decades, which has effectively improved the overall survival rate of patients, there is still no drug that can cure prostate cancer. Most existing drugs face the challenge of drug resistance, resulting in the inability of patients with advanced prostate cancer to receive effective treatment. Therefore, the development of new drugs for drug-resistant prostate cancer remains urgently needed in order to provide more effective treatment options. Summary of the invention

[0003] The first object of the present invention is to provide a citrinin derivative cladosporin C having anti-prostate cancer cell activity, the chemical structure of which is shown in formula (I):

[0004]

[0005] The second object of the present invention is to provide a method for preparing the above-mentioned compound cladosporin C, which is prepared by separating from the fermentation product of the marine fungus Talaromyces sp.SCSIO 41412. Specifically, the method comprises the following steps:

[0006] (a) preparing a fermentation product of fungus Talaromyces sp. SCSIO 41412;

[0007] (b) extracting the fermented product obtained in step (a) with ethyl acetate, and concentrating it by rotary evaporation to obtain a crude extract, and subjecting the crude extract to normal phase silica gel column chromatography, using petroleum ether / dichloromethane at a volume ratio of 0-100% and dichloromethane / methanol at a volume ratio of 0-100% for gradient elution, and combining to obtain fractions Frs.1-20 after TLC spot plate analysis, and fraction Fr.11 is separated by ODS reverse phase MPLC, and using methanol / water at a volume ratio of 10-100% for gradient elution. The fractions Frs.11-1-11-18 were obtained by elution with degrees, the fraction Fr.11-6 was eluted by semi-preparative HPLC with methanol / water / TFA at a volume ratio of 68:31.96:0.04 to obtain a mixed fraction Fr.11-6-3, the mixed fraction Fr.11-6-3 was eluted by semi-preparative HPLC with acetonitrile / water / TFA at a volume ratio of 46:53.96:0.04 to obtain the compound cladosporin C.

[0008] Preferably, the fermentation product in step (a) is prepared by the following method: the fungus Talaromyces p. SCSIO 41412 is inoculated into a PDB liquid culture medium, cultured on a shaking table, and then the cultured bacterial liquid is inoculated into a sterilized rice culture medium for fermentation to obtain a fermentation product.

[0009] Preferably, the PDB liquid culture medium contains 2.4% by mass of potato dextrose water, 2.5% by mass of sea salt, the remainder being water, and a pH of 7.4-7.8.

[0010] Preferably, the rice culture medium is obtained by mixing 225 mL of H2O and 12.5 g of sea salt per 180 g of rice.

[0011] The third object of the present invention is to provide an anti-prostate cancer drug, which comprises an effective amount of the compound cladosporin C or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.

[0012] Preferably, the content of the compound cladosporin C or its pharmaceutically acceptable salt in the drug is 1-99% by mass.

[0013] The fourth object of the present invention is to provide the use of the marine fungus Talaromyces sp. SCSIO 41412 in the preparation of the compound cladosporin C or its pharmaceutically acceptable salt, wherein the deposit number of the Talaromyces sp. SCSIO 41412 is GDMCC No: 64247.

[0014] In the process of studying the secondary metabolites of the fungus Talaromyces sp.SCSIO 41412 from the mangrove sediment, the present invention isolated and obtained a citrinin derivative cladosporin C, which has a significant inhibitory effect on prostate cancer cells and can inhibit the proliferation of PC-3 and 22Rv1 prostate cancer cells. 50 The values ​​are 6.51 and 9.25 μM, respectively, and can be used to prepare anti-prostate cancer drugs. Therefore, the cladosporin C of the present invention can be used as a supplementary option or a combined therapeutic drug option after resistance to androgen receptor antagonists such as enzalutamide, which is of great significance for the development of China's marine drug resources.

[0015] The fungus Talaromyces sp.SCSIO 41412 was deposited in the Guangdong Microbiological Culture Collection Center (GDMCC) on January 5, 2024, address: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences, Postal Code: 510070, and its deposit number is GDMCC No: 64247. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 The chemical structure of the polyketide citrinin derivative cladosporin C. DETAILED DESCRIPTION

[0017] In order to make the purpose, technical scheme and beneficial technical effect of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. It should be understood that the embodiments described in this specification are only for explaining the present invention, not for limiting the present invention.

[0018] Example 1 Fermentation of Talaromyces sp. SCSIO 41412 and Isolation of cladosporin C

[0019] (1) Strain isolation and preservation: The fungus Talaromyces sp. SCSIO 41412 was isolated from mangrove sediment and preserved in the Key Laboratory of Tropical Marine Bioresources and Ecology, Chinese Academy of Sciences.

[0020] (2) Fermentation: First, the strain preserved in paraffin oil was inoculated into a PDA plate (containing 4.01% potato dextrose agar by mass, 2.5% sea salt by mass, and the balance was water, pH 7.4-7.8) and cultured until new colonies grew, then inoculated into a PDB liquid medium (containing 2.4% potato dextrose water by mass, 2.5% sea salt by mass, and the balance was water, pH 7.4-7.8), and cultured at 28° C. in a shaking incubator (180 rpm) for 3 days, and then inoculated into a sterilized rice medium (180 g of rice, 12.5 g of coarse sea salt, and 225 mL of water) for fermentation. 80 bottles (about 14.4 kg of rice) were left to ferment at room temperature for 30 days to prepare a rice medium fermentation product of the fungus Talaromyces sp. SCSIO 41412.

[0021] (3) Extraction: After the fermentation of the rice culture medium, soak the culture medium with an equal volume of ethyl acetate for 24 hours, then crush it, ultrasonicate it for 15 minutes, and extract it with ethyl acetate three times until it is colorless. After rotary evaporation and concentration, combine and obtain a black crude extract (150.6 g).

[0022] (4) Separation: The crude extract was subjected to normal phase silica gel column chromatography, using petroleum ether / dichloromethane (0-100%, v / v) and dichloromethane / methanol (0-100%, v / v) for gradient elution, and 20 fractions (Frs.1-20) were obtained after TLC spot plate analysis. Fraction Fr.11 (dichloromethane / methanol 10%, v / v) was separated by ODS reverse phase MPLC gradient elution (CH3OH / H2O, volume ratio 10-100%) to obtain 18 small fractions (Frs.11-1-11-18). Fr.11-6 (CH3OH / H2O, volume ratio 30%) was separated and purified by semi-preparative HPLC (68% CH3OH / H2O (0.04% TFA), 3 mL / min) to obtain a mixed fraction Fr.11-6-3 (t R =8.5min). Fr.11-6-3 was separated by semi-preparative HPLC (46% CH3CN / H2O (0.04% TFA), 3mL / min) to obtain compound cladosporin C (18.3mg, t R =7.5min).

[0023] Example 2 Structural Identification of Cladosporin C

[0024] The chemical structure of the polyketide citrinin derivative cladosporin C isolated and obtained in Example 1 is shown in formula (I). The structure derivation process is as follows:

[0025]

[0026] Cladosporin C is yellow needle-shaped. Its molecular formula is C 14 H 16 O4(248), the degree of unsaturation is 8. The planar structure of the combined compound cladosporin C (such as Figure 1 shown) and 1 From the H NMR data (Table 1), we can see that the three methine signals (δ H / C 4.79 / 66.8; 3.54 / 77.4; 2.73 / 36.7) (including two carbon signals connected to oxygen), 1 methylene signal (δ H / C 2.94, 2.68 / 36.1), 1 aromatic hydrogen signal (δ H / C 6.42 / 100.2), 1 hydroxyl signal (δ H 9.75), 3 methyl signals (δ H / C 1.29 / 20.6; 1.12 / 18.6; 2.04 / 11.7). 13 C NMR data (Table 1) show that one carbonyl signal (δ C 166.8), 6 aromatic carbons (δ C 112.3, 156.0, 100.2, 146.7, 118.4, 138.0).

[0027] Table 1. Cladosporin C 1 H NMR and 13 C NMR data (500 and 125 MHz, deuterated DMSO)

[0028]

[0029]

[0030] Example 3 Cladosporin C Anti-prostate Cancer Cell Activity Test

[0031] (1) Cell culture: Prostate cancer 22Rv1 and PC-3 cells were purchased from the Cell Bank of the Chinese Academy of Sciences. The cells were cultured in a 37°C, 5% CO2 incubator using a culture medium containing 10% (v / v) fetal bovine serum. Before subculturing, the cells were carefully observed under an inverted microscope until the cell adherence density reached about 80%. The cells were collected for subculturing or plated for experiments.

[0032] (2) Effect of compounds on prostate cancer cell activity: Prostate cancer cells in the logarithmic growth phase were selected and digested with trypsin. The cell concentration was adjusted to 5.0×10 4After the cells were completely attached to the wall, the test compound was added (3 replicates), and the blank control group was added with complete culture medium containing 1% DMSO. After the compound was exposed for 72 hours, MTT reagent was added and the OD value at 570nm was detected.

[0033] (3) The inhibitory activity of cladosporin C on the proliferation of two prostate cancer cell lines, 22Rv1 and PC-3, was screened. The results showed that the compound cladosporin C showed stable moderate cytotoxicity against the prostate cancer cell lines PC-3 and 22Rv1. 50 The values ​​were 6.51±0.80 and 9.25±0.87 μM, respectively (Table 2).

[0034] Table 2. Inhibition of prostate cancer cell activity detection

[0035]

[0036]

[0037] In summary, cladosporin C inhibits the proliferation of prostate cancer cells PC-3 and 22Rv1, and can be used as a prostate cancer cell proliferation inhibitor for the development of anti-prostate cancer. The application of prostate cancer cell inhibitor cladosporin C in the preparation of anti-prostate cancer drugs suggests that cladosporin C has a potential therapeutic effect on prostate cancer and has a good clinical application prospect.

[0038] The above description is a detailed description of the preferred embodiments of the present invention, but the embodiments are not intended to limit the scope of the patent application of the present invention. All equivalent changes or modifications completed under the technical concept suggested by the present invention should fall within the scope of the patent covered by the present invention.

Claims

1. Use of the compound cladosporin C or a pharmaceutically acceptable salt thereof in the preparation of an anti-prostate cancer drug, wherein the structural formula of the compound cladosporin C is shown in formula (I):

2. A method for preparing a compound cladosporin C, characterized in that: The invention is separated and prepared from the fermentation product of marine fungus Talaromyces sp. SCSIO 41412. The deposit number of Talaromyces sp. SCSIO 41412 is GDMCC No: 64247.

3. The preparation method according to claim 2, characterized in that: The specific steps include: (a) preparing a fermentation product of fungus Talaromyces sp. SCSIO 41412; (b) extracting the fermented product obtained in step (a) with ethyl acetate, and concentrating it by rotary evaporation to obtain a crude extract, and subjecting the crude extract to normal phase silica gel column chromatography, using petroleum ether / dichloromethane at a volume ratio of 0-100% and dichloromethane / methanol at a volume ratio of 0-100% for gradient elution, and combining to obtain fractions Frs.1-20 after TLC spot plate analysis, and fraction Fr.11 is separated by ODS reverse phase MPLC, and using methanol / water at a volume ratio of 10-100% for gradient elution. The fractions Frs.11-1-11-18 were obtained by elution with degrees, the fraction Fr.11-6 was eluted by semi-preparative HPLC with methanol / water / TFA at a volume ratio of 68:31.96:0.04 to obtain a mixed fraction Fr.11-6-3, the mixed fraction Fr.11-6-3 was eluted by semi-preparative HPLC with acetonitrile / water / TFA at a volume ratio of 46:53.96:0.04 to obtain the compound cladosporin C.

4. The preparation method according to claim 3, characterized in that: The fermentation product in step (a) is prepared by the following method: the fungus Talaromyces sp. SCSIO 41412 is inoculated into a PDB liquid culture medium, and then the cultured bacterial liquid is inoculated into a sterilized rice culture medium for fermentation to obtain a fermentation product.

5. The preparation method according to claim 3, characterized in that: The PDB liquid culture medium contains 2.4% by mass of potato glucose water, 2.5% by mass of sea salt, and the balance is water, with a pH value of 7.4-7.

8.

6. The preparation method according to claim 3, characterized in that: The rice culture medium is obtained by mixing 180 g of rice with 225 mL of H2O and 12.5 g of sea salt.

7. A drug for treating prostate cancer, characterized in that: The invention comprises an effective amount of cladosporin C or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.

8. The drug according to claim 7, characterized in that The content of the compound cladosporin C or its pharmaceutically acceptable salt in the medicine is 1-99% by mass.

9. Use of the marine fungus Talaromyces sp. SCSIO 41412 in the preparation of the compound cladosporin C or its pharmaceutically acceptable salt, wherein the deposit number of the Talaromyces sp. SCSIO 41412 is GDMCC No: 64247.

Citation Information

Cited By

  • Microbial antioxidant pigment feed additive for aquaculture and preparation method thereof

    CN119776154A